Case Report: Durable complete response to olaparib in a patient with BRCA2-driven metastatic gastric adenocarcinoma after failure of chemo-immunotherapy
Metastatic gastric adenocarcinoma is associated with poor prognosis and limited treatment options after failure of chemotherapy and immunotherapy. Although BRCA1/2 alterations are well-established predictive biomarkers for PARP inhibitor efficacy in several malignancies, their role in gastric cancer...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Frontiers Media S.A.
2026-04-01
|
| سلاسل: | Frontiers in Oncology |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://www.frontiersin.org/articles/10.3389/fonc.2026.1769043/full |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|